|
[1]
|
J. A. Hutcheon, S. Lisonkova and K. S. Joseph. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Practice & Research Clinical Obstetrics and Gynaecology, 2011, 25(4): 391-403.
|
|
[2]
|
M. Hanssens, M. J. Keirse, B. Spitz and F. A. Van Assche. Measurement of individual plasma Angiotensins in normal pregnaney and pregnaney-indueed hypertension. Journal of Clinical Endocrinology and Metabolism, 1991, 73(3): 489-494.
|
|
[3]
|
H. Haller, E. M. Ziegler, V. Homuth, J. Eiehhom, Z. Nagy and F. C. Luft. Endothelial adhesion molecules and leukoeyte integrins in preeclamptic patients. Hypertension, 1997, 29(1 pt 2): 291- 296.
|
|
[4]
|
H. Haller, A. Hempel, V. Homuth, A. Mandelkow, C. Maaseh, M. Drab, et al. Endothelial cell permeability and protein kinase C in preeclampsia. Lancet, 1998, 351(9107): 945-949.
|
|
[5]
|
G. Wallukat, V. Homuth, T. Fisher, C. Lindsehau, P. B. Horstkam, A. Jupner, et al. Patients with Preeclampsia develop agonistic autoantibodies against the Angiotensin AT1 receptor. Journal of Clinical Investigation, 1999, 103(7): 945-952.
|
|
[6]
|
C. A. Hubel. Oxidative stress in the pathogenesis of preeclampsia. Proceedings of the Society for Experimental Biology and Medicine, 1999, 222(3): 222-235.
|
|
[7]
|
R. Dechend, C. Viedt, D. N. Muller, B. Ugele, J. Theuer, A. Fiebeler, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation, 2003, 107(12): 1632-1639.
|
|
[8]
|
A. Estellés, J. Gilabert, S. Grancha, K. Yamamoto, T. Thinnes, F. España, et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Journal of Thrombosis and Haemostasis, 1998, 79(3): 500-508.
|
|
[9]
|
R. Dechend, V. Homuth, G. Wallukat, J. Kleuzer, J. K. Park, J. Theuer, et al. AT(l) receptor agonistic antibodies from preeclamptic patient cause vascular cells to express tissue factor. Circulation, 2000, 101(20): 2382-2387.
|
|
[10]
|
Y. Xia, H. Y. Wen and R. E. Kellems. Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation. The Journal of Biological Chemistry, 2002, 277(27): 24601- 24608.
|
|
[11]
|
Y. Xia, H. Wen, S. Bobst, M. C. Day and R. E. Kellems. Matemal autoantibodies from Preeclamptic patients activate Angiotensin receptors on human trophoblast cells. Journal of the Society for Gynecologic Investigation, 2003, 10(2): 82-93.
|
|
[12]
|
S. M. Bobst, M. C. Day, L. C. Gilstrap, Y. Xia and R. E. Kellems. Maternal autoantibodies from preeclamptic patients activate Angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. American Journal of Hypertension, 2005, 18(3): 330-336.
|
|
[13]
|
A. Ahmed. Heparin-binding angiogenic growth factors in pregnancy. Trophoblast Research, 1997, 10: 215-258.
|
|
[14]
|
T. Nagamatsu, T. Fujii, M. Kusumi, L. Zou, T. Yamashita, Y. Osuga, et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: An implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology, 2004, 145(11): 4838-4845.
|
|
[15]
|
S. Ahmad, A. Ahmed. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circulation Research, 2004, 95(9): 884-891.
|
|
[16]
|
Y. Zhou, M. McMaster, K. Woo, M. Janatpour, J. Perry, T. Karpanen, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. American Journal of Pa-thology, 2002, 160(4): 1405-1423.
|
|
[17]
|
G. C. McKeeman, J. E. Ardill, C. M. Caldwell, A. J. Hunter and N. McClure. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. American Journal of Obstetrics & Gynecology, 2004, 191(4): 1240-1246.
|
|
[18]
|
E. D. Dimitrakova, J. D. Dimitrakov, S. A. Karumanchi, B. K. Pehlivanov, N. P. Milchev and D. I. Dimitrakov. Placental soluble fms-like tyrosine-kinase-1 (sFlt-1) in pregnant women with preeclampsia. Folia Medica (Plovdiv), 2004, 46(1): 19-21.
|
|
[19]
|
S. E. Maynard, J. Y. Min, J. Merchan, K. H. Lim, J. Li, S. Mondal, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation, 2003, 111(5): 649-658.
|
|
[20]
|
R. J. Levine, R. Thadhani, C. Qian, C. Lam, K. H. Lim, K. F. Yu, et al. Urinary placental growth factor and risk of preeclampsia. Journal of the American Medical Association, 2005, 293(1): 77- 85.
|
|
[21]
|
R. J. Levine, S. E. Maynard, C. Qian and K. H. Lim. Circulating Angiogenic factors and the risk of preeclampsia. The New England Journal of Medicine, 2004, 350(7): 672-683.
|
|
[22]
|
K. Koga, Y. Osuga, O. Yoshino, Y. Hirota, X. Ruimeng, T. Hirata, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. The Journal of Clinical Endocrinology & Metabolism, 2003, 88(5): 2348-2351.
|
|
[23]
|
C. C. Zhou, S. Ahmad, T. Mi, L. Xia, S. Abbasi, P. W. Hewett, et al. Angiotensin II Induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circulation Research, 2007, 100(1): 88-95.
|
|
[24]
|
C. C. Zhou, Y. Zhang, R. A. Irani, H. Zhang, T. Mi, E. J. Popek, et al. Angiotensin receptor agonistic autoantibodies induce pre- eclampsia in pregnant mice. Nature Medicine, 2008, 14(8): 855- 862.
|
|
[25]
|
R. A. Irani, Y. Zhang, C. C. Zhou, S. C. Blackwell, M. J. Hicks, S. M. Ramin, et al. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-α signaling. Hypertension, 2010, 55(5): 1246-1253.
|